DPL.BO · BSE
DIPNA PHARMACHEM LIMITED
₹4.54
+2.02% (+₹0.09)
Prev. close
₹4.45
Volume
21,000
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About DIPNA PHARMACHEM LIMITED
Dipna Pharmachem Limited imports, trades in, and exports pharmaceutical products primarily in India. It offers industrial chemicals, pharmaceutical raw materials, excipients, solvents, active pharmaceutical ingredients, formulations, and intermediates. The company was incorporated in 2011 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Pharmaceutical Retailers
CEO
Mr. Keyur Dipakkumar Shah
Headquarters
Ahmedabad
Website
dipnapharmachem.comExchange
View on BSE ↗Key stats
Market cap
₹11.94 Cr
P/E ratio (TTM)
11.1
EPS (TTM)
₹0.41
Beta (1Y · daily vs NIFTY 50)
0.45
Beta (5Y · monthly vs NIFTY 50)
0.39
Shares float
1.28 Cr
EPS · quarter ended Mar 2026
₹0.07
Financial Performance
01 · Financials
FY23 growth needs FY22 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹99.93 Cr | ₹164.34 Cr | ₹124.92 Cr | ₹129.08 Cr | |
| EBITDA | — | ₹2.35 Cr | ₹3.43 Cr | ₹5.02 Cr | ₹3.75 Cr |
| — | ₹91.20 L | ₹1.09 Cr | ₹2.63 Cr | ₹97.40 L | |
| Diluted EPS | ₹0.8 | ₹0.76 | ₹0.45 | ₹1 | ₹1 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Net income for Mar 2025 could not be independently verified against the company's own annual report: this page shows ₹2.63 Cr while the annual report gives ₹97.40 L (63.0% apart).
EBITDA for Mar 2025 could not be independently verified against the company's own annual report: this page shows ₹5.02 Cr while the annual report gives ₹3.45 Cr (31.4% apart).
09 · Balance Sheet
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹77.56 Cr | ₹132.91 Cr | ₹132.38 Cr | ₹205.63 Cr | |
| ₹15.91 Cr | ₹19.45 Cr | ₹17.22 Cr | ₹13.21 Cr | |
| Stockholders' equity | ₹24.36 Cr | ₹37.52 Cr | ₹38.49 Cr | ₹62.30 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹-20.98 Cr | ₹-5.42 Cr | ₹-9.19 Cr | ₹-18.32 Cr | |
| Investing cash flow | — | ₹-1.01 L | ₹-1.46 L | ₹-2.01 L | ₹-4.07 L |
| — | ₹26.47 Cr | ₹13.62 Cr | ₹-4.24 Cr | ₹18.80 Cr | |
| Capital expenditure | — | ₹-1.01 L | ₹-1.46 L | ₹-2.01 L | ₹-4.07 L |
| End cash position | — | ₹5.69 Cr | ₹13.88 Cr | ₹42.57 L | ₹86.30 L |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| DIPNA PHARMACHEM LIMITED | ₹11.70 Cr | ₹4.45 | 10.9 | 0.19 | 1.6% | 0.21 | -3.2% | -78.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.